Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bast

Showing results (91-100 of 560) with videos related to

Pageof 56
Sort By:
British Journal of Obstetrics and Gynaecology|December 1, 1993
Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3I J Jacobs, H Rivera, D H Oram, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 17, 2003
Targeted therapy for epithelial ovarian cancer: current status and future prospectsH T See, J J Kavanagh, W Hu, et al.
American Journal of Obstetrics and Gynecology|August 1, 1985
A study of the NB/7OK and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patientsS Knauf, D J Anderson, R C Knapp, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1971
Cutaneous basophil hypersensitivity. 3. Participation of the basophil in hypersensitivity to antigen-antibody complexes, delayed hypersensitivity and contact allergy. Passive transferH F Dvorak, B A Simpson, R C Bast, et al.
Communications Medicine|October 22, 2021
Next steps in the early detection of ovarian cancerRobert C Bast, Chae Young Han, Zhen Lu, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1989
CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovaryN Einhorn, R C Knapp, R C Bast, et al.
Advances in Experimental Medicine and Biology|January 1, 1985
Chemotactic anti-tumor antibodies: in vitro results with four different antibody preparationsR Obrist, J P Obrecht, R C Bast, et al.
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|January 7, 2011
The Roles of MicroRNAs in the Cancer Invasion-Metastasis CascadeXiao-Feng Le, Omar Merchant, Robert C Bast, et al.
Acta Oncologica (Stockholm, Sweden)|March 2, 1999
Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression modelL Pusztai, Z H Siddik, G B Mills, et al.
Journal of the National Cancer Institute|March 1, 1975
Antitumor activity of bacterial infection. I. Effect of Listeria monocytogenes on growth of a murine fibrosarcomaR C Bast, B Zbar, G B Mackaness, et al.
Pageof 56

Showing results (91-100 of 560) with videos related to

Sort By:
Pageof 56
British Journal of Obstetrics and Gynaecology|December 1, 1993
Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3I J Jacobs, H Rivera, D H Oram, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 17, 2003
Targeted therapy for epithelial ovarian cancer: current status and future prospectsH T See, J J Kavanagh, W Hu, et al.
American Journal of Obstetrics and Gynecology|August 1, 1985
A study of the NB/7OK and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patientsS Knauf, D J Anderson, R C Knapp, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1971
Cutaneous basophil hypersensitivity. 3. Participation of the basophil in hypersensitivity to antigen-antibody complexes, delayed hypersensitivity and contact allergy. Passive transferH F Dvorak, B A Simpson, R C Bast, et al.
Communications Medicine|October 22, 2021
Next steps in the early detection of ovarian cancerRobert C Bast, Chae Young Han, Zhen Lu, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1989
CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovaryN Einhorn, R C Knapp, R C Bast, et al.
Advances in Experimental Medicine and Biology|January 1, 1985
Chemotactic anti-tumor antibodies: in vitro results with four different antibody preparationsR Obrist, J P Obrecht, R C Bast, et al.
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|January 7, 2011
The Roles of MicroRNAs in the Cancer Invasion-Metastasis CascadeXiao-Feng Le, Omar Merchant, Robert C Bast, et al.
Acta Oncologica (Stockholm, Sweden)|March 2, 1999
Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression modelL Pusztai, Z H Siddik, G B Mills, et al.
Journal of the National Cancer Institute|March 1, 1975
Antitumor activity of bacterial infection. I. Effect of Listeria monocytogenes on growth of a murine fibrosarcomaR C Bast, B Zbar, G B Mackaness, et al.
Pageof 56